November 8, 2019
Takeda Pharmaceutical said on November 7 that its dengue vaccine candidate TAK-003 demonstrated in a global PIII trial protection against virologically-confirmed dengue (VCD), the trial’s primary endpoint. The study called TIDES evaluated over 20,000 subjects in Latin America and Asia,...read more